by Clinical Neuropsychologist | Monday, April 7, 2025 | Dementia
Abstract INTRODUCTION Neighborhood-level socioeconomic status (nSES) is associated with risk for cognitive impairment, but prior studies assessed nSES within an individual’s own residential area without considering the distribution of nSES among adjacent areas....
by Clinical Neuropsychologist | Monday, April 7, 2025 | Dementia
Abstract BACKGROUND Adults with Down syndrome (DS) have increased risk of Alzheimer’s disease (AD). The cholinergic system declines in AD, underlying many cognitive deficits. We investigated the relationship between amyloid accumulation and cholinergic terminal...
by Clinical Neuropsychologist | Wednesday, April 2, 2025 | Dementia
Abstract INTRODUCTION TRAILBLAZER-ALZ 6 (NCT05738486) is a multicenter, double-blind, ongoing phase 3b study in early symptomatic Alzheimer’s disease. METHODS Participants (n = 843) were randomized 1:1:1:1 (standard + three alternative donanemab dosing arms)....
by Clinical Neuropsychologist | Wednesday, April 2, 2025 | Dementia
Dementia, Ahead of Print. IntroductionCurrent support programs for individuals with dementia focus primarily on patients living with caregivers. Research on individuals with dementia living alone is sparse, with small sample sizes. This report describes data collected...
by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia
Abstract INTRODUCTION This study was undertaken to evaluate the diagnostic performance of a novel plasma phosphorylated tau (p-tau) 217/amyloid beta (Aβ) 42 ratio test for Alzheimer’s disease (AD). METHODS The diagnostic performance of the Lumipulse G plasma...
by Clinical Neuropsychologist | Saturday, March 29, 2025 | Dementia
Abstract INTRODUCTION It is unclear whether aggregated plasma protein risk scores (PPRSs) could be useful in predicting the risks of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). METHODS The Cox proportional hazard model with the Least Absolute...
